Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
Viruses · 2023
DOI: 10.3390/v15102052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Keita Fukao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka 561-0825, Osaka, Japan. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd..
Abstract (Originalsprache)
The small-molecule antiviral drug ensitrelvir targets the 3C-like protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study evaluated its inhibitory effect on viral replication in a delayed-treatment mouse model and investigated the relationship between pharmacokinetic (PK) parameters and pharmacodynamic (PD) effects. SARS-CoV-2 gamma-strain-infected BALB/c mice were orally treated with various doses of ensitrelvir starting 24 h post-infection. Effectiveness was determined 48 h after first administration based on lung viral titers. Ensitrelvir PK parameters were estimated from previously reported plasma concentration data and PK/PD analyses were performed. Ensitrelvir doses ≥ 16 mg/kg once daily, ≥8 mg/kg twice daily, or ≥8 mg/kg thrice daily for two days significantly reduced lung viral titers compared to that of the vehicle. PK/PD analyses revealed that mean AUC0–48h post-first administration, plasma concentration 48 h post-first administration (C48h), and total time above the target plasma concentration (TimeHigh) were PK parameters predictive of viral titer reduction. In conclusion, ensitrelvir dose-dependently reduced lung SARS-CoV-2 titers in mice, suggesting it inhibited viral replication. PK parameters C48h and TimeHigh were associated with sustained ensitrelvir plasma concentrations and correlated with the reduced viral titers. The findings suggest that maintaining ensitrelvir plasma concentration is effective for exerting antiviral activity against SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka 561-0825, Osaka, Japan.
- Research Area for Drug Candidate Generation II, Shionogi TechnoAdvance Research Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka 561-0825, Osaka, Japan.
ORCID-Profile: Haruaki Nobori, Teruhisa Kato, Takao Shishido
Förderung
- Shionogi & Co., Ltd.
Zitieren
APA
Fukao, K., Nobori, H., Kuroda, T., Baba, K., Matsumoto, K., Tanaka, Y., Tachibana, Y., Kato, T., & Shishido, T. (2023). Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model. Viruses. https://doi.org/10.3390/v15102052
Vancouver
Fukao K, Nobori H, Kuroda T, Baba K, Matsumoto K, Tanaka Y, et al. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model. Viruses. 2023. doi:10.3390/v15102052
BibTeX
@article{Fukao2023,
author = {Fukao, Keita and Nobori, Haruaki and Kuroda, Takayuki and Baba, Kaoru and Matsumoto, Kazumi and Tanaka, Yukari and Tachibana, Yuki and Kato, Teruhisa and Shishido, Takao},
title = {Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15102052}
}
EUVIMED